Brooks Laboratories amends AGM resolution for ₹48.15 crore BSL guarantee
- Brooks Laboratories issued an addendum on August 22, 2026, for its September 3 AGM
- Resolution 4 amended to ratify ₹48.15 crore guarantee for joint venture BSL
- Proposed FY27 related-party transaction limits total ₹35 crore plus guarantee
- Aggregate exposure represents 96.99% of prior year consolidated turnover

*this image is generated using AI for illustrative purposes only.
Brooks Laboratories Limited issued an addendum on August 22, 2026, to the notice of its 24th Annual General Meeting (AGM), scheduled for September 3, 2026. The update amends Resolution No. 4 to align with corporate guarantee arrangements involving its jointly controlled entity, Brooks Steriscience Limited (BSL). The company published the addendum in Financial Express and Jansatta on August 22, 2026.
The original AGM notice, dated July 31, 2026, and dispatched on August 12, 2026, remains valid except for the modifications detailed in the addendum. Shareholders must read the addendum collectively with the initial notice and the Annual Report for FY25-26.
Related Party Transaction Details
The amendment seeks shareholder approval to ratify a corporate guarantee of ₹48.15 crore provided in favor of BSL during March 2026. This guarantee was approved by the Audit Committee in its meeting held on February 6, 2026. The company proposes an overall corporate guarantee limit of up to ₹48.15 crore for BSL. Any further guarantees will require enhancement of this limit and applicable approvals.
In addition to the guarantee, the company proposes to continue operational transactions with BSL during FY26-27:
- Purchase of goods and commissions: up to ₹15 crore
- Sale of goods and commissions: up to ₹15 crore
- Job work services and shared services: up to ₹5 crore
The aggregate value of these transactions, including the corporate guarantee limit, represents approximately 96.99% of the company’s annual consolidated turnover for the immediately preceding financial year. Atul Ranchal is identified as a related party director interested in these transactions.
Other AGM Resolutions
The AGM agenda includes several other key resolutions:
- Cost Auditor Ratification: Ratification of remuneration payable to M/s. Balwinder & Associates for FY26-27 cost audit, amounting to ₹60,000 plus taxes.
- Director Reappointment: Reappointment of Mr. Jitendrapratap Rambahadur Singh, who retires by rotation.
- Executive Remuneration: Approval of remuneration for Mr. Atul Ranchal, President – Strategy, at a maximum of ₹15 lakh per month, effective September 1, 2026. Additionally, remuneration for Mr. Rajesh Mahajan, President – Trading, at a maximum of ₹8 lakh per month, effective July 17, 2026.
Key Dates and Logistics
The Register of Members will remain closed from August 27, 2026, through September 3, 2026. Remote e-voting opens on August 31, 2026, at 9:00 am and closes on September 2, 2026, at 5:00 pm. The AGM will be conducted exclusively via Video Conferencing or Other Audio-Visual Means (VC/OAVM), starting at 9:00 am IST.
| Event | Date/Time | Mode |
|---|---|---|
| AGM Date | September 3, 2026 | VC/OAVM |
| Start Time | 9:00 am IST | Virtual |
| Book Closure Start | August 27, 2026 | N/A |
| Book Closure End | September 3, 2026 | N/A |
| E-Voting Cut-Off | August 27, 2026 | N/A |
| Remote E-Voting Start | August 31, 2026, 9:00 am IST | Online |
| Remote E-Voting End | September 2, 2026, 5:00 pm IST | Online |
Shareholders are advised to ensure their email addresses are registered with their Depository Participants or the Registrar and Share Transfer Agent, MUFG Intime India Private Limited, to receive communications electronically. Attendance via VC/OAVM counts toward the quorum requirement under Section 103 of the Companies Act, 2013.
Historical Stock Returns for Brooks Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.88% | +2.40% | +9.67% | +5.15% | -56.59% | 0.0% |
How might the high concentration of related-party transactions, representing nearly 97% of turnover, impact Brooks Laboratories' operational independence and risk profile in FY26-27?
What are the specific strategic growth drivers for Brooks Steriscience Limited that justify the ₹48.15 crore corporate guarantee and continued financial support from the parent company?
Will the approved remuneration increases for President Atul Ranchal and President Rajesh Mahajan correlate with specific performance targets or expansion goals for the Strategy and Trading divisions?


































